Welcome New Members!
Trianni, Inc. is a biotech company specializing in antibody discovery. Our lead technology is a powerful next generation transgenic mouse platform for the isolation of fully human monoclonal antibodies.
Xperii is a software platform that's aiming to eliminate the inefficiency in participant recruitment by helping people participate in the research studies they are interested in through an automatic, streamlined process. Founded by a Brown University student and an MIT neuroscientist, Xperii's research study platform was conceptualized out of a personal need in recruiting participants for cognitive neuroscience studies at MIT.
The mission of XenoTherapeutics, Inc. is to advance the science of xenotransplantation through education, research, clinical testing and development towards a practical therapeutic use for the public benefit.
Obsidian Therapeutics, founded by Atlas Venture in 2016, is developing next-generation cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. We are based in Cambridge, MA and are actively seeking talented scientists to work in a fast-paced, innovative environment.
Silicon Therapeutic’s (STX) mission is to design novel therapeutics for the advancement of human health by building the most accurate in silico models of highly implicated human drug targets. STX has developed its own proprietary In Silico Targeted Engineering (INSITE) platform around this goal. Currently, we are applying the INSITE platform against target proteins that experience significant conformational change, which often renders them inaccessible to traditional drug discovery methods. STX plans to maintain scientific leadership in the field by first continuing to improve the science behind the INSITE platform, in addition to applying the INSITE platform to drive STX’s pipeline toward the clinic.
Platelets are the 'bandaids' of the bloodstream. They are the cells in your blood that stop you from bleeding. Over 2 million Americans receive life-saving platelet transfusions annually for cancer treatment, transplants and surgery. Platelets store for only 5 days due to bacterial contamination of product during collection from human donors.
Elstar Therapeutics in a privately-held biotechnology company in Cambridge, MA that has been formed by Apple Tree Partners, a $1.5B healthcare-focused venture capital firm based in NYC. Elstar's mission is to develop best-in-class multi-specific and multi-functional immunotherapies, empowered by the technical expertise and proprietary innovations. The company was founded by Andreas Loew, a veteran protein and antibody engineer and former global head of new technologies/biologics at the Novartis Institute of Biomedical Research (NIBR). Elstar Therapeutics leverages recent technical advances in antibody development to generate molecules with superior pharmacological properties that are capable of harnessing our growing understanding of immune system modulation to treat various diseases such as in oncology and autoimmunity.
Through internal research programs and external partnerships, SQZ Biotech is leading a revolution in scientists' approach to disease research and clinical therapies, developing novel methods to engineer cell function and harnessing the power of a patient's own cells to combat disease more effectively across a broad range of indications.
Founded in 1986, the National Fire Protection Association (NFPA) is a global, nonprofit organization devoted to eliminating death, injury, property and economic loss due to fire, electrical and related hazards. The association delivers information and knowledge through more than 300 consensus codes and standards, research, training, education, outreach and advocacy; and by partnering with others who share an interest in furthering the NFPA mission. For more information visit www.nfpa.org. All NFPA codes and standards can be viewed online for free at www.nfpa.org/freeaccess.
Conner Strong is a recognized leader in risk management and insurance for the life sciences industry. We specialize in providing insurance and risk management programs to emerging and established life science companies nationwide. We have been serving the industry for over 20 years and have a unique understanding of the complex issues that affect life science companies. Our expertise encompasses a wide breadth of coverages dealing with product liability/clinical trials, directors' and officers' liability, professional liability-errors and omissions, laboratory/production property exposure, executive benefits and group employment benefit plans.
TraceLink helps life science companies securely supply every global market opportunity on-time and in-full through the TraceLink Business Cloud, a cloud-based application platform that connects business transactions, partner networks and professional relationships across companies and functions to form a high-performance, collaborative business network.
We are moving the needle for clinical trials. Are you frustrated with the time it takes to commercialize a drug? So are we. Do you wish you could decrease your study start-up timelines by up to 4 weeks? Take the guesswork out of supply forecasting? Make changes midstream without expensive trial delays? Well, now you can. At 4G, our mission is to move the needle in clinical trials. Our robust, efficient approach to RTSM provides enhanced visibility into your trials, enabling you to do your job better and spend your time and resources wisely to get drugs to patients faster.
Pharmaron is a premier R&D service provider for the pharmaceutical industry. Founded in 2003, Pharmaron has invested in our people and our facilities, enabling us to provide high quality R&D service across a number of disciplines including chemistry, biology, DMPK, pharmacology, toxicology and chemical development. Pharmaron has grown steadily to meet the needs of our customers. With over 3,000 employees and operations in China and the U.S., Pharmaron delivers superior scientific services while maintaining close communication with our customers. Our current clients include small and large pharmaceutical companies in North America, Europe, Japan and China.
Chestnut Pharma is seeking a cure for metastatic cancers. The company is targeting their oncology therapeutics toward a ‘master switch’ they discovered that enables cancer cells to undergo a major cellular transition to adopt an aggressive state and become metastatic while impairing the immune system through several distinct mechanisms.